Ultralife (NASDAQ:ULBI) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 57.14 percent. This is a 1200 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $42.98 million which beat the analyst consensus estimate of $42.00 million by 2.34 percent. This is a 34.68 percent increase over sales of $31.92 million the same period last year.
Ultralife Corporation (NASDAQ:ULBI) has been added to the Russell 2000® Index and the broad market Russell 3000® Index as part of the 2024 annual reconstitution of the index, effective at the open of the U.S. equity market today, July 1, 2024.
Benchmark analyst Josh Sullivan maintains Ultralife (NASDAQ:ULBI) with a Buy and raises the price target from $13 to $14.
NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to
NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin
NEWARK, N.Y., July 01, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has been added to the Russell 2000® Index and the broad market Russell 3000® Index as part of the 2024 annual reconstitution of the index, effective at the open of the U.S. equity market today, July 1, 2024. "The inclusion of Ultralife in the Russell 2000® Index, one of the most widely used performance benchmarks for small-cap companies, testifies to the substantial improvement in the Company's financial profile and earnings power as we began to realize returns on our customer-driven new product investments and to recapture margins while continuing to advance our transformational projects for our commercia
Benchmark initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation ("Ultralife" or the "Company") (NASDAQ:ULBI) has appointed Michael E. Manna as the Company's President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company. Mr. Popielec will remain with Ultralife as an employee for a sixty-day period ending January 20, 2023 in an advisory role to ensure a smooth leadership transition. In addition to his new role, Mike Manna will retain his leadership position for the Company's Battery & Energy Products segment which he held prior to his appointment as President & CEO. "Over the past twe
SC 13D/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to
NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin
NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of $0.02 for the 2023 first quarterAdjusted EBITDA of $5.2 million, a four-fold gain compared to $1.2 million last yearBacklog of $97.4 million exiting the 202
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
10-Q - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)